Patients with metastatic non-small cell lung cancer (NSCLC) face an increased risk of early disease progression when treated with dual immunotherapy—nivolumab plus ipilimumab—compared to chemotherapy, according to an exploratory analysis of the CheckMate 227 and CheckMate 9LA trials. While this immunotherapy regimen offers significant long-term survival benefits for some, clinicians are now identifying baseline factors, such as low tumor mutational burden and high inflammatory markers, that may signal which patients require more intensive initial treatment strategies.
Why does early progression occur with dual immunotherapy?
Rapid progression, defined as disease advancement or death within three months of starting treatment, affected 40% of patients receiving nivolumab plus ipilimumab in the CheckMate 227 trial, compared to 26% of those receiving chemotherapy. This early detriment often occurs because immunotherapy requires time to prime the immune system, leaving the tumor unchecked during the initial weeks of therapy. According to the study data, this “early-risk period” is most pronounced in patients with limited tumor immunogenicity, where the immune system fails to mount a rapid, effective response against the cancer cells.
Long-term survivors of dual immunotherapy typically exhibit higher baseline tumor mutational burden (TMB) and lower levels of systemic inflammation, suggesting that a patient’s pre-treatment biological profile is a primary indicator of durable response.
Which biomarkers identify patients at risk?
Researchers identified several baseline factors associated with a higher likelihood of early failure during immunotherapy-only treatment. Using multivariable models, the analysis highlighted five key indicators:
- High neutrophil-to-leukocyte ratio
- Tumor mutational burden (TMB) below 14 mutations per megabase
- PD-L1 expression below 1%
- Low serum albumin levels
- Higher-than-median monocytic myeloid-derived suppressor cell levels
These markers suggest that patients with systemic inflammation or a suppressed immune environment may not benefit from immunotherapy alone in the immediate term. The study authors emphasize that relying on a single biomarker, such as PD-L1, is insufficient. Instead, a multimodal approach—viewing inflammatory markers, nutritional status, and genomic data together—provides a more accurate assessment of a patient’s risk profile.
Does adding chemotherapy mitigate early risk?
The addition of two cycles of platinum-doublet chemotherapy to nivolumab plus ipilimumab appears to neutralize the risk of early progression, according to findings from the CheckMate 9LA trial. In this cohort, rapid progression occurred in 27% of patients receiving the combination therapy, nearly identical to the 28% rate observed in patients treated with chemotherapy alone. This suggests that the early chemotherapy cycles provide necessary tumor control while the immunotherapy agents work to establish a durable, long-term immune response.
When discussing first-line options with patients, consider their need for immediate symptom relief versus long-term disease control. For patients with high tumor burden or aggressive clinical presentation, the combination of chemotherapy and immunotherapy may be safer to avoid the early-detriment phase associated with immunotherapy monotherapy.
What are the implications for clinical practice?
While these findings are hypothesis-generating and require prospective validation, they shift the focus toward personalized treatment selection. Clinicians are encouraged to look beyond standard genomic testing. For example, a patient with low TMB and high systemic inflammation might be better served by a regimen that includes chemotherapy to bridge the gap until the immunotherapy takes effect. The study serves as a reminder that the “one-size-fits-all” approach to checkpoint blockade is evolving into a more nuanced strategy where clinical and laboratory variables dictate the intensity of the initial regimen.
Frequently Asked Questions
Is TMB the most important factor for choosing immunotherapy?
No. While TMB below 14 mutations per megabase was a strong predictor of early progression, it is not a standalone biomarker. It must be interpreted alongside other factors like albumin levels and systemic inflammation.
Can chemotherapy be safely added to dual immunotherapy?
Yes. Data from CheckMate 9LA shows that adding two cycles of chemotherapy does not interfere with the long-term benefits of immunotherapy and helps prevent early disease progression.
Are these findings applicable to all NSCLC patients?
These findings specifically apply to patients with metastatic NSCLC without sensitizing EGFR mutations or ALK rearrangements. Always consult current clinical guidelines and individual patient markers before adjusting treatment plans.
Are you a healthcare professional treating patients with metastatic NSCLC? Stay updated on the latest immunotherapy research by subscribing to our oncology clinical newsletter for regular updates on trial data and treatment protocols.